MCAM and prostate carcinoma: To meet the above purpose, first, this modified LFIA had been greatly improved from the traditional LFIA to become an accurate, simple, and rapid diagnostic method for comparing the concentrations of the human METCAM/MUC18 antigens in serums from normal human individuals with those from prostate cancer patients.